Pergocoat 2 mg Film-coated Tablets for Horses

Oral use, once daily.
To facilitate administration, the required daily dose should be placed in a small
amount of water and/or mixed with molasses or other sweetener and agitated until
dissolved. In this case, the dissolved tablets should be administered with a syringe.
The whole amount should be administered immediately. Tablets should not be
crushed, see section 4.5.
Starting dose
The starting dose is about 2 µg pergolide/kg (dose range: 1.3 to 2.5 µg/kg; see table
below). The maintenance dose should then be titrated according to the individual
response as determined by monitoring (see below), resulting in an average
maintenance dose of 2 µg pergolide/kg bodyweight with a dose range of 0.6 to 10 µg
pergolide/kg bodyweight.

Revised: August 2023
AN: 01887/2022 & 01334/2022Page 4 of 7
Starting doses are recommended as follows:
Horse body
weight
0.5 mg
tablet
1 mg
tablet
2 mg
tablet
Starting
dose
Dosage
range
200 - 400 kg0.5 mg
1.3 – 2.5
μg/kg
401 - 600 kg1.0 mg
1.7 – 2.5
µg/kg
or
401 - 600 kg1.0 mg
1.7 – 2.5
µg/kg
601 - 850 kg+1.5 mg
1.8 – 2.5
µg/kg
or
601 - 850 kg1.5 mg
1.8 – 2.5
µg/kg
851 - 1000 kg2.0 mg
2.0 – 2.4
µg/kg
or
851 - 1000 kg2.0 mg
2.0 – 2.4
µg/kg
Maintenance dose
Lifelong treatment is anticipated for this disease.
Most horses respond to therapy and are stabilised at an average dose of 2 µg
pergolide/kg body weight. Clinical improvement with pergolide is expected within 6 to
12 weeks. Horses may respond clinically at lower or varying doses; it is therefore
recommended to titrate to the lowest effective dose per individual based on response
to therapy, whether it is effectiveness or signs of intolerance. Some horses may
require doses as high as 10 µg pergolide/kg body weight per day. In these rare
situations, appropriate additional monitoring is advised.
Following initial diagnosis, repeat endocrinologic testing for dose titration and
monitoring of treatment at intervals of 4 to 6 weeks until stabilisation or improvement
of clinical signs and/or diagnostic testing occurs.
If clinical signs or diagnostic testing have not yet improved at the first 4 to 6 week
interval, the total daily dose may be increased by 0.50 mg. In case clinical signs have
improved but are not yet normalised, the veterinarian may decide to titrate or not to
titrate the dose, considering the individual’s response/tolerance to the dose.

Revised: August 2023
AN: 01887/2022 & 01334/2022Page 5 of 7
In case clinical signs are not adequately controlled (clinical evaluation and/or
diagnostic testing) it is recommended to increase the total daily dose by 0.5 mg
increments (if the drug is tolerated at that dose) every 4 to 6 weeks until stabilisation
occurs. If signs of dose intolerance develop, treatment should be stopped for 2 to 3
days and reinstated at one-half of the previous dose. The total daily dose may then
be titrated back up to the desired clinical effect by 0.5 mg increments every 2 to
4 weeks. If a dose is missed, the next scheduled dose should be administered as
prescribed.
Following stabilisation, regular clinical assessment and diagnostic testing should be
performed every 6 months to monitor treatment and dose. Where there is no
apparent response to treatment, the diagnosis should be re-evaluated.